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Skeletal muscle makes up 40–50% of body mass, and is thus considered to be a
good adult stem cell source for autologous therapy. Although, several stem/progenitor
cells have been fractionated from mouse skeletal muscle showing a high potential for
therapeutic use, it is unclear whether this is the case in human. Differentiation and
therapeutic potential of human skeletal muscle-derived cells (Sk-Cs) was examined.
Samples (5–10 g) were obtained from the abdominal and leg muscles of 36
patients (age, 17–79 years) undergoing prostate cancer treatment or leg amputation
surgery. All patients gave informed consent. Sk-Cs were isolated using conditioned
collagenase solution, and were then sorted as CD34−/CD45−/CD29+ (Sk-DN/29+) and
CD34+/CD45− (Sk-34) cells, in a similar manner as for the previous mouse Sk-Cs.
Both cell fractions were appropriately expanded using conditioned culture medium for
about 2 weeks. Differentiation potentials were then examined during cell culture and
in vivo transplantation into the severely damagedmuscles of athymic nude mice and rats.
Interestingly, these two cell fractions could be divided into highly myogenic (Sk-DN/29+)
and multipotent stem cell (Sk-34) fractions, in contrast to mouse Sk-Cs, which showed
comparable capacities in both cells. At 6 weeks after the separate transplantation of both
cell fractions, the former showed an active contribution to muscle fiber regeneration, but
the latter showed vigorous engraftment to the interstitium associated with differentiation
into Schwann cells, perineurial/endoneurial cells, and vascular endothelial cells and
pericytes, which corresponded to previous observations with mouse SK-Cs. Importantly,
mixed cultures of both cells resulted the reduction of tissue reconstitution capacities
in vivo, whereas co-transplantation after separate expansion showed favorable results.
Therefore, human Sk-Cs are potentially applicable to therapeutic autografts and show
multiple differentiation potential in vivo.
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Introduction
Skeletal muscle organ/tissue comprises 40–50% of body mass,
and it undergoes marked changes postnatally as a result of
physical over-load or disuse, known as muscle hypertrophy and
atrophy, respectively. Basically, skeletal muscle is composed of
major four tissues as: (1) muscle fibers; (2) peripheral nerve
networks; (3) blood vessel networks; and (4) connective tissue
networks. Therefore, it is possible that the volume and/or cell
number of these tissues are also changeable via whole muscle
hypertrophy or atrophy. This phenomenon also suggests that
skeletal muscle tissue must contain stem and/or progenitor
cells that can support increases in the above tissues. Indeed,
our previous studies have indicated that multipotent stem cell
populations, which could synchronously reconstitute themuscle-
nerve-blood vessel units following cellular differentiation into
skeletal muscle cells, Schwann cells, perineurial/endoneurial
cells, vascular endothelial/smooth muscle cells, pericytes and
fibroblasts, are present in the mouse skeletal muscle (Tamaki
et al., 2002, 2003, 2005, 2007a,b). Stem cells in skeletal muscle
have been fractionated by various methods, including pre-plating
culture series (Lee et al., 2000; Torrente et al., 2001; Qu-Petersen
et al., 2002), repeated culture following the freeze-thaw technique
(Williams et al., 1999; Young et al., 2001; Romero-Ramos et al.,
2002) and fluorescence activated cell sorting (FACS) with cell
surface makers (Tamaki et al., 2002) or with Hoechest dye
(Gussoni et al., 1999; Jackson et al., 1999; Majka et al., 2003;
Tamaki et al., 2003). However, because of these variations in
isolation/fractionation methods, it is difficult to directly compare
the origin, localization and differentiation potentials of these
stem cells. Therefore, there are no standard methods for the
isolation of practical stem cells from skeletal muscles.
Nevertheless, the ultimate aim of stem cell research is the
safe clinical application of the transplantation therapy. For this
purpose; in the present study, we fractionated human skeletal
muscle-derived cells (Sk-Cs), taking advantage of the typical
characteristics of our isolation methods; such as the soft cell
isolation without mincing of muscles, and cell sorting in the
freshly isolated state, following the previous series of mouse
experiments (Tamaki et al., 2002, 2003, 2005, 2007a,b, 2008a,b,
2010). Appropriate cell markers for purification and culture
conditions to obtain sufficient cell expansion were examined with
regard to safety, rapidity and stability, as well as preservation of
subsequent in vivo differentiation capacity.
Results indicated that the human Sk-Cs can be
divided into three fractions, CD34−/CD45−/CD29+
(Sk-DN/29+), CD34+/CD45−/CD29+ (Sk-34/29+) and
CD34+/CD45−/CD29− (Sk-34/29−), similarly to mouse
Abbreviations: Sk-Cs, skeletal muscle-derived cells; Sk-DN/29+ cells,
CD34−/CD45−/CD29+ cells; Sk-34 cells, CD34+/CD45−; FACS, fluorescence
activated cell sorting; DMEM, Dulbecco’s modified essential medium; FCS, fetal
calf serum; IMDM, Iscove’s modified Dulbecco’s medium; TA, tibialis anterior; G,
gastrocnemius; S, soleus; A, rectus abdominis; VM, vastus medialis; VL, vastus
lateralis; PBS, phosphate-buffered saline; PFA, paraformaldehyde; PB, phosphate
buffer; SMA, smooth muscle action; DAPI, 4′,6-diamino-2-phenylindole; DAB,
3,3′-Diaminobenzidine; SkMA, skeletal muscle actin; HNA, human nuclear
antigen.
Sk-Cs. Interestingly, these cell fractions could also be divided
into highly myogenic (Sk-DN/29+) and multipotent stem
cell (Sk-34/29+/−) fractions, in contrast to mouse Sk-Cs.
After separate transplantation of human Sk-DN/29+ and
Sk-34/29+/− cells into the damaged muscles of nude mice and
rats, the former showed active contributions to muscle fiber
regeneration, and the latter showed vigorous engraftment to the
interstitium following differentiation into neural Schwann cells,
perineurial/endoneurial cells, and vascular endothelial cells and
pericytes. Therefore, the present preparation method for human
Sk-Cs is potentially applicable to therapeutic autografts, thereby
allowing efficient use of their multiple differentiation potentials
in vivo, as was indicated by our previous mouse experiments.
Materials and Methods
Human Skeletal-muscle Samples and Cell
Isolation
Samples (5–10 g) were obtained from the abdominal, tibialis
anterior, soleus, gastrocnemius, vastus-medialis, and vastus-
lateralis muscles of 36 patients (age, 17–79 years) undergoing
prostate cancer (n= 27) or leg amputation (n= 9) surgery. Study
protocols were approved by our institutional ethics committee,
and all patients gave consent after being informed of the study
aims and procedures. Abdominal muscles were obtained from
around the camera-port in laparoscopic surgery, and leg muscles
were obtained from amputated, but retained non-damaged tissue
portion. Muscle samples were wrapped in gauze moistened with
cold (4◦C) physiological saline immediately after removal, and
were transferred to the laboratory for isolation of stem cells
within 30min.
Stem cells were isolated using a procedure corresponding to
that previously described for mouse muscles (Tamaki et al., 2002,
2003). Briefly, muscle samples were weighed and washed several
times with Dulbecco’s modified essential medium (DMEM) with
1% penicillin/streptomycin, and were cut into several pieces (5–
7mm in thickness and width, and 40–50mm in length). Muscles
were never minced. Muscle pieces were treated with 0.1%
collagenase type IA (Sigma-Aldrich, St. Louis, MO) in DMEM
containing 7.5% fetal calf serum (FCS) with gentle agitation
for 2 h at 37◦C. Extracted cells were filtered through 70-µm,
40-µm and 20-µm nylon strainers in order to remove muscle
fibers and other debris, and were then washed and resuspended
in Iscove’s modified Dulbecco’s medium (IMDM) containing
10% FCS, yielding enzymatically extracted cells. Enzymatically
extracted mixed cells were then, prepared for staining with cell
surface antigens and sorting, or were stored in liquid nitrogen
using cell preservative solution (Cell Banker; Juji-field, Tokyo,
Japan) until use, after pre-freezing at −80◦C using a bio freezing
vessel (BICELL; Nihon Freezer Co., Ltd, Tokyo, Japan).
Flow Cytometry and Sorting of Enzymatically
Isolated Cells
First, in order to characterize the enzymatically isolated cells
and to determine the appropriate markers, FACS analysis
was performed on freshly isolated human Sk-Cs using typical
mesenchymal stem cell surface makers: CD29, CD31, CD44,
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CD56 (NCAM) and CD73 (purchased from BD Biosciences,
Dan Jose, CA); CD105 and CD117 (c-kit) (from BioLegend, San
Diego, CA); CD133 (from Miltenyi Biotec, Bergisch Gladbach,
Germany); and CD166 (from Beckman Coulter, Brea, CA); as
well as CD34 (RAM34; eBioscience, San Diego, CA) and CD45
(30-F11; BioLegend, San Diego, CA) antibodies. Cell analysis
and sorting were carried out on a FACSAria (Becton Dickinson
Japan, Tokyo, Japan). Note that the same cell characterizationwas
also performed for expanded cells cultured under the conditions
described blow. Consequently, based on the results for freshly
isolated cells (see Figure 1A), we decided to sort human Sk-Cs
using CD29, CD34 and CD45, and obtained the CD34+/45−/29+
(Sk-34/29+), CD34+/45−/29− (Sk-34/29−), CD34−/45−/29+
(Sk-DN/29+), and CD34−/45−/29− (Sk-DN/29−) fractions (see
Figures 1B,C).
Determination of Proper Culture Condition and
Cytokines
In order to determine optimal culture conditions for cell
expansion, we first selected 10 cytokines, as summarized in
Supplemental Table 1, based on previous reports. Permutations
and combinations of these cytokines were performed for the
three cell fractions above using 24-well plates. IMDM was used
as a basic culture medium. Evaluation was performed as follows;
(1) 1000 cells/well were cultured to confluence; (2) cells were
detached using 0.05% trypsin EDTA (Life Technologies, Tokyo,
Japan), re-plated in 25-cm2 flasks, and cultured to confluence;
and (3) cells were re-plated in 75-cm2 flasks and cultured to
confluence. Expanded cells at each stage were photographed,
and the time (days) to attain confluence were determined and
compared.
On the other hand, some of these expanded cells were
further cultured with repetitive passages (until 10 passages) and
increasing culture terms. Finally, expanded cells were harvested
and counted, and analyzed as follows; (1) FACS analysis (see
above); (2) karyotype checking; (3) myotube formation test; (4)
expression of specific mRNAs; and (5) transplantation analysis
(see below).
Karyotype Checking
Karyotype abnormalities were examined using colchicine and
Giemsa stain at various stages (passages and terms) of cell culture
up to 10 passages. Cells were arrested in metaphase during cell-
division with a solution of colchicine (0.01% for 6 h), harvested
using 0.05% trypsin EDTA (Life Technologies), and pelleted by
centrifugation at 1000 rpm for 5min. Cells were re-suspended
in hypotonic KCl solution (0.075M) for 15min at 37◦C, and
were fixed with Carnoy fixative. After repeated washing of cells,
Giemsa staining was performed, and the stained cell pellet was
dropped on a slide glass and dried at 56◦C. Finally, 20 cells in
metaphase were analyzed by G-banding in each selected sample.
Myotube Formation Test
After determination of optimal culture conditions, we performed
myotube formation testing in 3 cell fractions. Myotube formation
was simply induced by reducing serum concentrations from 20
to 5% (Table 1) and by addition of HGF (20 ng/ml), as these
FIGURE 1 | Expression of CD markers in freshly isolated and expanded
(passage 1) Sk-Cs. (A) Freshly isolated total cells were positive for 6 out of 11
markers, and predominant markers were CD29 and CD34; thus, these were
used for subsequent cell fractionation. However, expression of these markers
markedly changed after culture of both Sk-DN/29+ and Sk-34/29+/− cells,
but importantly, the characteristics of both cells were similar after expansion.
(B) Actual sorting for the exclusion of CD45+ cells, as hematopoietic cells. (C)
Basic sorting pattern of 3 cell fractions, as Sk-DN/29+, Sk-34/29+ and
Sk-34/29−, which was consistently used throughout the present study. Data
were obtained from 21 subjects/32 samples (Male n = 19, age 21–79; Female
n = 2, age 17–69, from abdominal muscle n = 16, leg muscles n = 5).
conditions induced themost active myotube formation in human
cells.
RT-PCR Analysis for Expanded Sk-Cs
After optimal culture conditions were confirmed, RT-PCR was
performed on expanded (passages 1–4) Sk-DN/29+, Sk-34/29+,
and Sk-34/29− cells in order to test for expression of specific
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TABLE 1 | Optimal culture conditions for human Sk-34 and Sk-DN cells.
Awaking medium Proliferation medium (from passage 1)
Common use Sk-34/29+/− fraction Sk-DN/29+ fraction
Basic contents IMDM IMDM IMDM
20%FBS 20%FBS 20%FBS
0.1mM 2-Mercaptethanol 0.1mM 2-Mercaptethanol 0.1mM 2-Mercaptethanol
50µg/ml gentamicin 50µg/ml gentamicin 50µg/ml gentamicin
Additional contents 0.4 ng/ml EGF 0.4 ng/ml EGF 0.4 ng/ml EGF
12.5 ng/ml bFGF 12.5 ng/ml bFGF 12.5 ng/ml bFGF
20 ng/ml IGF-1 20 ng/ml IGF-1
4mg/ml Dexamethasone
markers of skeletal muscle, peripheral nerve and vascular cell
lineages. Specific primers and analyzedmaterials are summarized
in Supplemental Table 2. Cells were lysed and total RNA was
purified using a QIAGEN RNeasy micro kit. First-strand cDNA
synthesis was performed with an Invitrogen SuperScript III
system using dT30-containing primer (see above), and specific
PCR (35 cycles of 30 s at 94◦C, 30 s at 60–65◦C and 2min
at 72◦C) was performed in a 15-µl volume containing Ex-Taq
buffer, 0.8 U of ExTaq-HS-polymerase, 0.7µM specific sense
and antisense primers, 0.2mM dNTPs and 0.5µl of cDNA.
Analysis was performed for 3–6 samples in each fraction and
for each passage, and relative expression intensity was classified
into 3 levels, based on the housekeeping-control gene (GAPDH).
Obtained values were averaged.
Transplantation into Damaged Tibialis Anterior
(TA) Muscle
In order to determine in vivo differentiation potential, optimally
cultured-expanded (2 passages) human Sk-DN/29+ and Sk-
34/29+/− cells were transplanted into the severely damaged TA
muscle model, which was removed about 30–40% of muscle
fragments with nerve and blood vessel branches from the region
around the motor point (Tamaki et al., 2005). For in vivo
transplantation analysis, sufficient numbers of Sk-34/29− cells
could not be obtained through the same process as the other
two cell fractions. In addition, it was confirmed by RT-PCR
analysis that the characteristics of Sk-34/29− cells did not affect
the total characteristics of Sk-34/29+ cells. Thus, we combined
the Sk-34/29+ and /29− cell fractions, and cultured/expanded
them together, and then performed the transplantation study.
Cells were transplanted into traumatic muscle damage with
large deficits in muscle-nerve-blood vessel units in the athymic
nude mouse (female, BALB/cA Jcl-nu/nu; CLEA Japan, Tokyo,
Japan, age 5–6 wk, n = 14) and/or rat (male and female,
F344/NJcl-mu/mu; CLEA, Tokyo, Japan, age 8–12 wk, n = 4)
TA muscle. Surgery and cell transplantation were performed
under inhalation anesthesia (Isoflurane; Abbott, Tokyo, Japan).
The left TA muscle of nude mice was exposed by skin incision,
and its fascia was minimally cut. Using forceps, muscle fibers
with nerve and blood vessels were manually removed (17.1 ±
0.9mg) from the region surrounding the motor point of the
TA muscle. The large incision were sutured, and then cells (5.2
± 1.5 × 105) suspended in 2∼3µl of DMEM were injected
slowly into the damaged muscle portion using a fine tip glass
micropipette, in order to avoid diffusion of transplanted cells.
Then, a transparent sterile/analgesic plastic dressing (Nobecutan
spray; Yoshitomi Chemical, Japan) was sprayed over the wound.
The right TA muscle was preserved as a control. At 6–8 weeks
after transplantation, recipient mice were given an overdose
of pentobarbital (60mg/kg, i.p.), and were perfused with
warm 0.01M phosphate-buffered saline (PBS) through the left
ventricle, followed by fixation with 4% paraformaldehyde/0.1M
phosphate buffer (4% PFA/PB). TA muscles were then removed
and re-fixed overnight in 4% PFA/PB, washed with graded
sucrose 0–25%/0.01M PBS series, and were quick frozen in
isopentane pre-cooled with liquid nitrogen, followed by storage
at −80◦C until use. This in vivo cell engraftment/differentiation
analysis were performed using the samples of 16 subjects (male:
n = 14, age 17–79; female: n = 2, age 17; 8 abdominal and
8 leg muscles) with 52 times transplantations. All experimental
procedures were approved by the Tokai University School of
Medicine Committee on Animal Care and Use (No. 142035,
142034). All experiments were performed in the Tokai University
School of Medicine and Hospital.
Immunocytochemistry, Immunohistochemistry,
and Immunoelectron Microscopy
Cell differentiation potential in vitro was examined by
immunocytochemistry. For the staining of cultured cells,
each culture well was fixed with 4% PFA/PB for 10min. After
washing with 0.01M PBS, cells were stained with anti-Pax7
(mouse monoclonal, 1:50 overnight at 4◦C; Developmental
Studies Hybridoma Bank, University of Iowa, Iowa, IA) or
MyoD (mouse monoclonal, 1:50, overnight at 4◦C, 5.8A; DAKO,
Carpinteria, CA) to detect the myogenic cells and putative
muscle satellite cells, respectively. Similarly, cultured cells were
suspended in trypsin-EDTA and prepared for cytospin analysis.
Cell differentiation potential in vivo was examined by
immunohistochemistry and immunoelectron microscopy. For
staining of histological sections, several 7 − µm cross-sections
of operated TA muscles were obtained. Engrafted human cells
were detected by anti-human nuclear antigen (HNA, 1:100, 4◦C
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overnight; clone 235-1, Cy3 conjugate, Millipore, Temecula, CA).
Blood vessels were detected using mouse monoclonal αSMA
(Cy3-conjugated directly; 1:1500, for 1 h at room temperature;
Sigma, Saint Louis, MO), rat anti-mouse CD31 (1:500, 4◦C
overnight; BD Biosciences, San Jose, CA), and rabbit polyclonal
anti-human CD31 (1:200, for 2 h at room temperature, Abcam,
Cambridge, UK). Pericytes were detected by the combination use
of rabbit polyclonal anti-NG2 (1:100, 1 h at room temperature;
Millipore) and anti/human CD31. Immature and/or newly
differentiated Schwann cells were detected using rabbit anti-
p75 (1:400, 4◦C overnight; CST, Boston, MA) polyclonal
antibody, in relation to the myelin formations detected by rabbit
polyclonal anti-myelin basic protein (MBP; 1:200, for 2 h at
room temperature; Millipore, Billerica, MA). Muscle fibers were
detected with rabbit polyclonal anti-skeletal muscle actin (1:300,
for 1 h at room temperature; Abcam, Cambridge, UK). Rabbit
polyclonal anti-laminin (Pan-laminin, 1:1500 for 2 h at room
temperature, LSL, Tokyo, Japan) and/or rat monoclonal anti
mouse laminin (β-2 chain, 1:2000 for 2 h at room temperature,
Chemicon, Temecula, CA) antibodies were used to distinguish
muscle fibers and interstitial spaces. Reactions were visualized
using Alexa Fluor-488- and 594- conjugated goat anti-rabbit and
anti-rat antibodies (1:500, for 2 h at room temperature;Molecular
Probes, Eugene, OR). Nuclei were counter-stained with DAPI
(4′,6-diamino-2-phenylindole).
For immunoelectron microscopy, sections were stained using
anti-HNA (1:50, 4◦C overnight; clone 235-1, biotin conjugate;
Millipore) and followed by HRP-conjugated streptavidin second
antibody (1:200, for 1 h at room temperature; DAKO) in
order to label engrafted human cells. Reactions were visualized
with DAB (3, 3′-Diaminobenzidine) after fixation in 1%
glutaraldehyde/0.1M phosphate buffer. Visualized sections were
then fixed in 1% osmium tetroxide/0.05M phosphate buffer,
and were prepared for electron microscopic analysis. Cell
differentiation into Schwann cells, perineurial/endoneurial cells,
vascular endothelial cells and pericytes, and fibroblasts were
mainly observed. Immunoelectron microscopy was performed as
described previously (Tamaki et al., 2005, 2007a, 2008a,b, 2010).
Quantitative Analysis
Cells specifically determined by immunocytochemistry
on cultured and/or cytospin preparation were counted
using Photoshop (Adobe Systems Inc., San Jose, CA)
or Stereo Investigator (MBF Bioscience, Williston, VT)
software. Immunohistochemically positive/negative cells were
photographed by the unit area to wholly cover all distributing
cells (6–12 area), and were averaged and expressed as percentages
(positive/total cells).
Results
Cell Characterization by CD Markers for the
Freshly Isolated and after Expansion Culture
State
Freshly isolated human Sk-CDs were characterized using 11
candidate CD makers, and they were typically negative for
CD105, CD133, CD166, c-kit, and NCAM (CD56) (Figure 1A).
Less than 5% positivity was observed for CD31, CD44, CD45
and CD73, and over 10% positivity was observed for CD29 and
CD34. Therefore, we decided to sort human Sk-Cs using CD29
and CD34, in addition to CD45, due to its elimination role for
hematopoietic cells. The basic sorting pattern for freshly isolated
human Sk-Cs is shown in Figures 1B,C. Human cells showed a
similar pattern as mouse cells under sorting by CD45 and CD34
(Figure 1A), which was reported previously (Tamaki et al., 2002,
2003, 2005, 2007a,b, 2008b). No CD34+/CD45+ cells were seen
among human Sk-Cs, and this is a difference from mouse Sk-
Cs (Figure 1B). Cells in the Sk-DN and Sk-34 fractions were
further divided into 4 fractions; CD34+/45−/29+ (Sk-34/29+),
CD34+/45−/29− (Sk-34/29−), CD34−/45−/29+ (Sk-DN/29+),
and CD34−/45−/29− (Sk-DN/29−) fractions (Figure 1C). We
have previously sorted freshly isolated cells from murine skeletal
muscle by CD34 and CD45, and simply obtained Sk-34 and Sk-
DN cells (Tamaki et al., 2002, 2003, 2005, 2007a,b, 2008b). In this
method, however, the Sk-DN fraction tended to include debris
and unnecessary non-stem cells. This contaminating debris must
be avoided in human therapy. As expected, the Sk-DN/29−
fraction included debris and non-proliferative cells; thus, we
eliminated this fraction from further experiments.
Figure 1A also shows a comparison of marker expression
between freshly isolated and 2-wk (passage 1) expanded Sk-
DN/29+ and Sk-34/29+/− cells. These expanded cells were
subjected to further in vitro and in vivo analysis. Note that
the characteristics of these 2 cell populations after expansion
culture were similar. Both cell populations consistently expressed
a high percentage of CD105, CD166, NCAM (CD56), CD29,
CD44 and CD73, and the remaining markers showed 0%
positivity. Although these populations showed the same cell
surface markers, there were differences in the in vitro and in vivo
cell differentiation capacities (see below).
Determination of Optimal Culture Conditions
Through a series of experiments, we determined the optimal
awaking and proliferation media for the Sk-34 and Sk-DN cell
fractions, as shown in Table 1. Basically, activation of human
cells occurred more slowly when compared with mouse cells (4–7
days). Therefore, the awaking medium is important, and was the
same for both the Sk-DN and Sk-34 cell fractions. However, the
proliferationmedium differed, and these optimal conditions were
selected to give higher proliferation maintaining cell immaturity,
as progressive differentiation during culture reduces the potential
for tissue engraftment and reconstitution. Consequently, 300∼
450-fold increases in the number of cells were achieved during
the 14–16-day culture period, through 1–3 passages, with 9–12
cell doublings. We consistently used these culture conditions in
further in vitro and in vivo experiments.
With regard to karyotyping through long-term cell culture
(around 10 passages), we detected abnormalities in 4 cases; 1
cases in Sk-DN/29+ cells (deletion of short arm chromosome
17), and 3 cases in unsorted bulk cell cultures (trisomy
of chromosome 8, translocation of chromosome 10 and 11,
translocation of chromosome 18 and 20). There were no
abnormalities found in the Sk-34 cell fractions. The common
factors in these 4 cases were continuous use of dexamethasone
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in the proliferating culture medium over 5 passages (mainly
appeared in 8–9 passages) and over 40 days of the total
culture term. However, use of dexamethasone in the awaking
medium in the first week of culture is effective for both Sk-DN
and Sk-34 cell expansion and safety. Therefore, we eliminated
dexamethasone from the proliferating medium (see Table 1). In
addition, unsorted bulk cell culture was also a risk factor; thus,
it should be avoided. Cell sorting before culture is therefore
important. Consequently, the awaking and proliferating culture
conditions were modified to avoid all of these risk factors.
Furthermore, we eliminated HGF because it accelerated
myotube formation in both Sk-DN and Sk-34 cells. This was
considered to be unsuitable for maintaining an immature state,
which is necessary for therapeutic use.
Behaviors of Sk-DN/29+, Sk-34/29+, and
Sk-34/29− Cells In Vitro
Typical cellular behaviors in the three cell fractions are
shown in Figure 2. Comparisons were performed in the 25-
cm2 flask (see Methods). Cell behaviors differed in the Sk-
DN/29+ (Figures 2A,B), Sk-34/29+ (Figures 2C,D), Sk-34/29−
(Figures 2E,F) and Sk-34 (29+/−, Figure 2G) cell fractions. The
former two cell fractions showed full confluence after 2 weeks
of conditioned culture with 1 passage (Figures 2A,C), whereas
Sk-34/29− cells showed 50–60% cell density (Figure 2E). When
these cells were cultured in normal control medium (with
20%FCS only), less than 50% cell density was obtained with
both Sk-DN/29+ (Figure 2B) and Sk-34/29+ (Figure 2D) cells,
even after 4–5 weeks of culture, which was 2-times longer
than with conditioned medium. Furthermore, Sk-34/29− cells
did not grow well in normal control media (Figure 2F). This
difference demonstrates the efficacy of the present conditioned
culture method. Owing to the lower increasing ratio for Sk-
34/29− cells, we performed combined culture of Sk-34/29+
and /29− cell fractions using the same procedure (Figure 2G),
and obtained better confluence than with solo culture of Sk-
34/29+ cells (Figures 2C,G). Thus, combined expansion of
total Sk-34 cells (unsorted by CD29) was more useful for
further study and therapeutic use. Interestingly, co-expansion
culture of Sk-DN/29+ and Sk-34 cells showed accelerated
differentiation/commitment, and greater cell numbers were
obtained (data not shown). Thus, it was considered to be
unsuitable for further therapeutic cell expansion.
Subsequently, the distribution of putative satellite cells
(Pax7-positive cells) and myogenically committed cells (MyoD-
positive cells) were determined by the combined use of
immunocytochemical analysis for cytospin, and cultured Sk-
DN/29+ and Sk-34 cells preparations at passages 0–4 (Figure 3).
A large number of Pax7+ cells were observed among Sk-DN/29+
cells (Figures 3A,B), but few were present among Sk-34 cells
(Figures 3C,D), both on cytospin (Figures 3A,C) and cell culture
(Figures 3B,D). Interestingly, Pax7 expression could be clearly
divided into strong and weak reactions. Sk-DN/29+ cells also
showed stronger Pax7 reactions, with few weak reactions (arrows
in Figure 3A). In contrast, the total number of Pax7+ cells in
the Sk-34 fraction was apparently less than that in Sk-DN/29+
cells (Figures 3A,C), and most showed weak reactions (arrows
FIGURE 2 | Typical cellular behaviors in culture for three cell fractions.
(A,B) Sk-DN/29+, (C,D) Sk-34/29+, (E,F) Sk-34/29−, and (G) Sk-34 (29+/−).
Cell behaviors were apparently different in the 4 cell fractions. The left column
shows the results after 2 weeks of expansion culture in conditioned medium.
The right column shows control medium (IMDM/20%FCS with antibiotics only)
without any additional cytokines. Favorable cell proliferation was apparent in
conditioned medium in each cell fraction, as compared to control. However,
Sk-34/29− cells showed significantly lower proliferation (E), but when two
Sk-34 cells (29+/−) were prepared for combined culture, improved confluence
of cells was obtained (G). Behaviors of Sk-DN/29− cells were also presented in
Supplemental Figure 1. Bars= 100µm. In this analysis, over 1250 well plates
from 22 subjects/38 samples (Male n = 20, age 21–79; Female n = 2, age
17–69, from abdominal muscle n = 16, leg muscles n = 6) were used.
in Figure 3C). The same trend was confirmed under culture
conditions, as there were no strong reactions among the Sk-
34 cells (arrows in Figure 3D, as compared to Figure 3B). The
number of Pax7- and MyoD-positive cells in both cell fractions
were counted following passages 0–4 (Figure 3E). Pax7+ cells
were evaluated as either strong or weak reactions. Among Sk-
DN/29+ cells, over 75% of total Pax7+ cells were observed
in P0, and gradually decreased with each passage (P1 = 62%,
P2= 32%, and P4 = 15%) and this trend did not change when
it was evaluated by strong reactions only. In addition, active
myogenic commitment accounting for 30–40% MyoD+ cells
was observed at P0 and P1; however, this markedly decreased
after P2. In contrast, in Sk-34 cells, total Pax7+ cells were
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FIGURE 3 | Distribution of Pax7- and MyoD-positive cells in the
Sk-DN/29+ and Sk-34 fractions. Typical expression of Pax7 in
Sk-DN/29+ (A,B) and Sk-34 (C,D) cells at passage 1. (A,C) Cytospin
preparation. (B,D) Culture dish preparation. A large number of Pax7+ cells
were observed among Sk-DN/29+ cells, but few were seen among Sk-34.
Note that cells positive for Pax7 typically contained several weak reactions
(arrows in A and C). This trend did not change in either cytospin or culture
dish preparations. (E) Serial changes in the number of Pax7+ and MyoD+
cells from PO to P4, expressed as percentages of total cells are shown.
Strong myogenic potential was detectable in Sk-DN/29+ cells, but was
weak in Sk-34. Bars = 50µm. Data were obtained from 11 samples
(M40-VM, VL; M45-TA, G; M57-A; M58-A; M59-A; M61-A; F17-TA, S, G).
counted around 30–40% during P0–P1, and clearly decreased
after P2. Similarly, strong reactions for Pax7 disappeared after P2,
while no myogenic commitment (detection of MyoD+ cells) was
observed through Sk-34 cell expansion culture. Thus, myogenic
commitment of Sk-34 cells appears to be rare in vitro.
Myotube formation test was also performed for Sk-DN/29+
and Sk-34 cells (Figure 4). Sk-DN/29+ cells showed active
formation of myotubes associated with the expression of
MyoD and SkMA (Figure 4A). Solo MyoD+ cells also showed
cellular elongation (arrows in Figures 4A,B). These responses
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FIGURE 4 | Myotube formation test for Sk-DN/29+ and Sk-34 cells.
(A,B) Sk-DN/29+. (C,D) Sk-34 cells. There were numerous multinucleated
myotubes formed in Sk-DN/29+ cells, but very few in Sk-34 cells. Myogenic
potential was strong in Sk-DN/29+ cells, but was quite weak in Sk-34 cells.
Single MyoD-positive cells (arrows) were also observed. Bars = 50µm. Data
were obtained from 11 samples (M67-A, VL; M45-TA, G; M57-A; M58-A;
M59-A; M61-A; F17-TA, S, G).
demonstrate the high myogenic potential of Sk-DN/29+ cells
in vitro. In contrast, Sk-34 cells showed no multinucleated
myotube formation, and few MyoD+ cells were observed;
however, there were SkMA+/− cells present (arrows in
Figures 4C,D), suggesting lower myogenic potential. This
myotube formation capacity gradually decreased following cell
passage, even in Sk-DN/29+ cells (data not shown). Therefore,
it is likely that 2–3 passages is the limit for the present cell
expansion method for myogenic therapeutic use.
RT-PCR Analysis
In order to support the immunocytochemical data, we performed
RT-PCR analysis in relation to skeletal myogenic, peripheral
nerve and vascular lineage makers for the 3 cell fractions
before and after culture (Figure 5). In the freshly sorted state
(before culture), Sk-DN/29+ cells expressed skeletal myogenic
marker mRNAs, whereas Sk-34/29+/− cells showed non-skeletal
myogenic characteristics. Please note that the Sk-34 fraction
before culture was tested as total Sk-34 cells (CD29+/−). After
culture (P1 stage), however, differences were detected in the
expression of skeletal myogenic markers (black bars), and other
peripheral nerve (blue bars) and vascular (red bars) makers were
similar in the 3 groups. Expression of c-met, M-cad, Scn1b and
NCAM were similar in the 3 groups; however, there was no
expression of MyoD, Myf-5, Pax3, Pax7, Myogenin and SkMA in
the Sk-34/29− cells. However, this expression was strong in Sk-
DN, and weak in the Sk-34/29+ cells. Lack of Pax7 expression was
common in both the Sk-34/29+ and /29− fractions. These results
correspond to the results for immunocytochemistry andmyotube
formation (Figures 3, 4). Therefore, Sk-DN cells showed strong
myogenic potential, while Sk-34/29+ showed weak potential, and
Sk-34/29− cells showed none. These expression patterns after
culture did not largely change through 5 passages. Therefore,
taken together with the above immunocytochemical data, mRNA
expression levels do not appear to be affected by cell passage,
whereas protein expression levels aremarkedly reducedwith each
passage.
The characteristics of Sk-34/29− cells appeared to be
consistent with those of Sk-34/29+ cells with regard to protein
and mRNA levels, and they were thought to compatible during
cell expansion culture. Therefore, combined culture of total
Sk-34 cells was considered to be suitable, because of the
higher efficiency of cell expansion (see Figure 2) for therapeutic
purposes.
In Vivo Differentiation Capacity after
Transplantation into Severely Damaged Skeletal
Muscle
In order to determine in vivo cell differentiation capacity,
both Sk-DN/29+ and total Sk-34 cells were transplanted into
severely damaged TA muscle (Figures 6, 7). At 4–6 weeks after
transplantation, a large number of HNA+ myofibers nuclei were
seen in Sk-DN/29+ cell-transplanted muscles, and there were
few HNA+ nuclei in the interstitium (Figure 6A). HNA+ nuclei
were located inside the fiber basal lamina filled with SkMA
(Figures 6B,C). In contrast, after Sk-34 cell transplantation, most
HNA+ nuclei were distributed in the interstitium, and there were
very few inside the muscle fibers (Figure 7A). Interstitial HNA+
nuclei were mainly distributed around the p75+ Schwann cells
(Figure 7B) and/or SMA+ blood vessels (Figure 7C). Some of
the p75+ Schwann cells included HNA+ nuclei, representing
donor human cell-derived Schwann cell formations (arrows in
Figure 7B). Similarly, some HNA+ nuclei were located near
SMA+ blood vessels (arrows in Figure 7C).
Detailed differentiation of interstitial cells having HNA+
nuclei following Sk-34 cell transplantation was also confirmed
by the higher magnification immunofluorescence and
immunoelectron microscopy (Figures 8, 9). The SMA+
cells including HNA+ nuclei were evident (Figure 8A, arrows),
and human CD31+ reactions were also observed closely around
the HNA+ nuclei (Figure 8B, arrows). In addition, NG2+
cells were also HNA+ just around the mouse CD31+ reactions
(Figure 8C, arrows). These results indicated that engrafted Sk-34
cells differentiated into vascular smooth muscle cells, endothelial
cells and pericytes, and contributed to the formation of blood
vessels. Similarly, HNA+/p75+ cells close to MBP+ reactions
were evident (Figure 8D, arrows) showing the differentiation
into Schwann cells, and contribution to nerve regeneration.
In the immunoelectron microscopy, HNA+ reactions
were visualized by DAB; thus, they appeared as black dots
in immunoelectron micrographs, thus, it made darker
nuclei (compare between numbered and arrowed nuclei in
Figure 9A). Distributions of HNA+ cells were quite similar to
immunofluorescence. Donor human Sk-34 cells differentiated
into Schwann cells (1), perineurial/endoneurial cells with
perineurium/endoneurium (2, 3), and vascular endothelial
cells (4), pericytes (5) and fibroblasts (6), and contributed to
peripheral nerve and blood vessel regeneration (Figures 9A,B).
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FIGURE 5 | RT-PCR analysis of Sk-DN/29+ and Sk-34 cells before
and after expansion culture. Bars in black color shows myogenic
markers, blue shows peripheral nerve, and red shows vascular
markers. Green shows common markers in the three lineages.
Expression intensity was normalized based on the housekeeping-control
gene (GAPDH), and values were averaged. These data supported the
results of immunocytochemical analysis and myotube formation test. In
addition, it was clear that Sk-DN/29+ cells comprised already
committed myogenic cells in a freshly isolated state (see before), but
Sk-34 cells did not include myogenic cells. Data were obtained from
21 subjects/36 samples (Male n = 20, age 21–79; Female n = 1, age
17, from abdominal muscle n = 16, leg muscles n = 5).
We also performed the same transplantation of unsorted and
expanded cells, which supposed to be included Sk-DN and Sk-34
cells, but they exhibited a reduced engraftment ratio and tissue
reconstitution capacity, probably due to their accelerated cell
differentiation/commitment during expansion culture (data not
shown).
Discussion
In the present study, we demonstrated through in vitro and
in vivo analysis that human SK-Cs could be divided into two
typical cell populations that differentiate into: (1) a myogenic
lineage, sorted as human Sk-DN/29+ cells; and (2) peripheral
nerve support and vascular cell lineages sorted as human Sk-34
cells. It is also possible that human Sk-DN cells are mainly
composed Pax7+ putative satellite cells, which was confirmed
by cell behaviors (tube formation) in vitro, and in vivo muscle
fiber regeneration. In contrast, human Sk-34 cells were non-
myogenic and supported peripheral nerve and blood vessel
tissue reconstitution. Consequently, human skeletal muscle
contains stem or progenitor cells that are able to differentiate
into muscle-nerve-blood vessel unit-related cell lineages. This
corresponds to the results of our previous reports in mouse
skeletal muscle (Tamaki et al., 2005, 2007a,b). However, mouse
Sk-DN cells are situated hierarchically upstream of Sk-34 cells
(Tamaki et al., 2008b), and exert the same cell differentiation and
tissue reconstitution capacities for damaged muscle-nerve-blood
vessel units (Tamaki et al., 2007a,b). At present, the relationship
between human Sk-DN/29+ and Sk-34 cells is unknown.
However, when these two cell populations are cultured/expanded
together, differentiation/commitment of both cells was
unnecessarily accelerated, and in vivo cell engraftment efficiency
and tissue reconstitution capacity was markedly reduced. This
may be profoundly detrimental to the subsequent ability to
regenerate skeletal muscle in vivo (Montarras et al., 2005). Thus,
Sk-DN/29+ and Sk-34 cells should be expanded separately.
However, co-transplantation of separately expanded both
cells showed synergistic effects, as there were large number of
HNA+ cells detected in both the interstitial space and in the
muscle fibers (Figure 10). Thus, the combined or separate use for
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FIGURE 6 | Typical engraftment of Sk-DN/29+ cells in damaged
muscle at 6 weeks after transplantation. (A) Wide view of the
transplanted portion. Pink = HNA (human nuclear antigen), green =
laminin (basal lamina staining) and blue (nuclear staining by DAPI).
Most HNA+ nuclei were located in the basal lamina of muscle fibers.
Panels (B,C) show the same areas stained with HNA + laminin +
DAPI (B), and SkActin (skeletal muscle actin) + laminin (C) taken at
higher magnification. HNA+ nuclei were clearly located in the muscle
fibers (arrows). M17-VM = Male 17 year-old, vastus lateralis. Bars =
50µm.
regeneration of myofibers and/or peripheral nerve-blood vessel
networks is possible, depending on therapeutic application, and
this is considered to be one of the beneficial points of the present
method.
Several stem cell populations in the human skeletal muscle
have been sorted by FACS in the freshly isolated state (Zheng
et al., 2007, 2012; Vauchez et al., 2009; Lecourt et al., 2010; Pisani
et al., 2010; Bareja et al., 2014). However, the characteristics
of isolated cells do not correspond between previous reports
and the present study. The most important point is the
inclusion or detection of CD56+ cells in the freshly isolated
state, and this is common to the above reports, whereas our
method did not include CD56+ cells. Cells having differentiation
potential for myogenic and endothelial cells were fractionated
as myoendothelial cells co-expressing CD56, CD34 and CD144,
in contrast to other CD56+ myogenic cells (Collins et al.,
2005; Zheng et al., 2012). Myogenic populations were also
sorted as CD56+ and CD34+/− cells in relation to their
association with adipogenic potential (Pisani et al., 2010),
and with additional use of CD15 (Lecourt et al., 2010). On
the other hand, myogenic/adipogenic cells were also isolated
using aldehyde dehydrogenase activity (ALDH) and CD34+/−
reactions (Vauchez et al., 2009), but were negative for CD31,
CD45, CD56 and CD140b, which is similar to the present study,
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FIGURE 7 | Typical engraftment of Sk-34 cells in damaged muscle at 6
weeks after transplantation. (A)Wide view of transplanted portion. Pink =
HNA (human nuclear antigen), green = laminin (basal lamina staining), and
blue (nuclear staining by DAPI). Most HNA+ nuclei were located in the
interstitial spaces of muscle (outside of muscle fiber basal lamina). (B,C) show
the same areas stained with HNA + p75 (green, Schwan cell marker) + DAPI
(B), and HNA+ SMA (green, smooth muscle actin, vascular smooth muscle
marker) + DAPI (C) taken at higher magnification. Co-staining with HNA and
p75 was evident, showing Schwann cell differentiation of engrafted human
cells (arrows in B). Similar co-staining was also observed in (C, arrows), thus
suggesting differentiation of engrafted cells into vascular smooth muscle cells.
F17-G = Female 17 year-old, gastrocnemius. Bars = 50µm.
but this report actually included 20min of pre-incubation with
Aldefluor assay buffer. Thus, it is also unclear how this treatment
affects the expressions of these markers.
Differences in the basic cell isolation method were considered
to have a strong effect on this issue (Collins et al., 2005).
Particularly, when using enzymatic digestion, proteolytic
contamination can damage cell surface ligands or receptors,
which are necessary for stem cell function after in vivo
transplantation (Collins et al., 2005). We have thus consistently
used lower concentrations of collagenase (0.1%) in DMEM and
always add 5–10% FBS to the collagenase solution in order to
minimize contaminating protease activity and to protect isolated
cells. This is a milder treatment when compared with previous
studies, which have used higher concentrations of collagenase
(0.2–2.0%) without suppression of protease activity, followed
by dispase (0.25%) and/or trypsin (0.1–0.25%) treatments.
Furthermore, we never mince donor muscle before enzymatic
digestion in contrast to the all other reports, and sample
dissection is kept to a minimum (to produce 6 × 6 × 40mm
samples; see Methods). Therefore, there are several reasons
that our isolated cells showed fewer available cell markers
and better differentiation potential after transplantation than
in other reports. This is also the case in our previous mouse
skeletal muscle experiments, in which cell isolation resulted in
minimal contamination from other cell types, such as committed
endothelial cells. In fact, we first identified Myo-endothelial
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FIGURE 8 | Detection of cell differentiations by higher
magnification immunofluorescences at 6 weeks after Sk-34 cell
transplantation. (A, arrows) SMA+/HNA+ cells located around blood
vessel showing differentiation of engrafted human cells into vascular
smooth muscle cells. (B, arrows) Anti-human CD31+/HNA+ cells were
also observed around the blood vessel, showing differentiation into
vascular endothelial cells. (C, arrows) NG2+/HNA+ cells located just
around the mouse CD31+ blood vessel, showing differentiation into
pericytes. (D, arrows) p75+/HNA+ cells were also located close to
myelin (MBP+), showing differentiation into Schwann cells. F17-S, G,
TA = Female 17 year-old, soleus, gastrocnemius, tibiaris aterior.
Bars = 20µm.
cells from mouse skeletal muscle as Sk-34 cells, but there were
no CD31+ cells present among them (Tamaki et al., 2002),
nor were there CD133− or NCAM (CD56)-expressing cells
(Tamaki et al., 2008a) when using our method. Consequently,
the present human cell surface marker expression was similar
to our previous mouse study, but did not correspond to other
reports of the mouse or human skeletal muscle.
On the other hand, the present results also indicate that
cell surface marker expression after culture are not useful
for the classification of cellular differentiation capacity, as
there were no typical differences observed between Sk-DN
and Sk-34 cells after culture (Figure 1A), while the actual
cell behaviors in culture (Figures 2–5) and cell differentiation
potential in vivo (Figures 6–9) were clearly different. Therefore, a
direct comparison of the characteristics in the human Sk-Cs with
cells fractionated by other researchers after expansion and/or
series culture (Young et al., 1999, 2001; Alessandri et al., 2004;
Wei et al., 2011; Chirieleison et al., 2012) is difficult. Nonetheless,
we believe that long-term culture of Sk-Cs, including satellite
cells, has a profoundly detrimental effect on their subsequent
ability to regenerate skeletal muscle in vivo, because cells begin
to differentiate in culture (Montarras et al., 2005).
With regard to therapeutic potential, cellular engraftment
capacity and cryopreservation are also important factors. In
previous studies, the immunodeficient SCID mouse (Skuk et al.,
2006; Zheng et al., 2007, 2012; Meng et al., 2011; Chirieleison
et al., 2012) or more specific animals, such as Rag2−/−γc−/−
mouse (Cooper et al., 2001; Vilquin et al., 2005; Riederer
et al., 2008; Pisani et al., 2010; Meng et al., 2011) have
generally been selected as recipients animals, in order to obtain
better cell engraftment ratios. However, we used the athymic
nude mouse, which meets the minimum requirements of a
Frontiers in Physiology | www.frontiersin.org 12 June 2015 | Volume 6 | Article 165
Tamaki et al. Multi-potency of human muscle-derived cells
FIGURE 9 | Detection of cells having HNA+ nuclei following 6 weeks of
Sk-34 cell transplantation by immunoelectron microscopy. (A) Relatively
wide interstitium.(B) Relatively narrow interstitium. HNA+ reactions were
visualized with DAB; thus, they appeared as black dots. Numbers and letters
inserted in the panels correspond to cells and/or tissues listed on the bottom of
the photos. Differentiation into 1–6 cell lineages was confirmed. Arrows in (A)
show HNA-negative nuclei, which is free of black dots. Details of the
determination of HNA+ cells in the immunoelectron microscopy are presented
in Supplemental Figure 2. F17-G = Female 17 year-old, gastrocnemius. Bars
in A = 20µm, and in B = 5µm.
recipient animal model for cell transplantation, and sufficient
engagement was observed (see Figures 6–9). The results were
not significantly different when nude rats were used as recipients
(compare Figures 10A,B). Therefore, this may indicate a higher
engraftment capacity for present human Sk-DN and Sk-34 cells.
In addition, we also confirmed that cryopreservation is suitable
for the present human Sk-Cs. The most effective and practical
cryopreservation method is when enzymatically isolated cells are
washed with DMEM/10% FCS, immersed in cell preservative
solution, set into a specific cell freezing container, and then stored
at −80◦C. After 24 h, cells can be transferred to liquid nitrogen
FIGURE 10 | Typical engraftment of human Sk-DN/29+ and Sk-34 cells
at 8 weeks after co-transplantation. (A) Co-transplantation into severely
damaged tibialis anterior (TA) muscle of nude mouse. (B) Co-transplantation
into severely damaged tibialis anterior (TA) muscle of nude rat. Favorable and
active engraftment of HNA+ nuclei into muscle fibers and interstitium was
observed under both transplantation conditions. Therefore, synergistic effects
are promising in co-transplantation of Sk-DN/29+ and Sk-34 cells, while
co-expansion culture showed poor results. This is similar to the case of solo
transplantation of mouse Sk-DN or Sk-34 cells (see References. Tamaki et al.,
2005, 2007a,b). In comparison to solo human Sk-DN/29+ transplantation in
Figure 6, the number of fibers including HNA+ nuclei is likely low. This may
depend a reason that the number of transplanted Sk-DN cells were absolutely
reduced half because of the addition of Sk-DN + Sk34 cells, under adjustment
to the total cell number of solo transplantation.
and stored. Stored cells were thawed and awaked at 37◦C, washed
with DMEM/10%FCS, and prepared for standard CD marker
staining and cell sorting. Using this cryopreservation method,
weaker cells are lost, but sufficient numbers are maintained, and
the capacities for consecutive cell sorting, expansion culture and
in vivo engraftment/differentiation remained favorable.
Finally, there were no significant effects of the age,
gender and muscle region for the isolated cellular
proliferation/differentiation capacities observed between
samples, whereas the age of subjects ranged 17–79. Superficially,
it is curious, because the age dependent decrease in muscle
mass, motor functions, and ability of regeneration is generally
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FIGURE 11 | The cell doubling of Sk-34 (A) and Sk-DN/29+ (B) cells. Note that there are not all samples appeared, because some were directly used for in vivo
transplantation study, and some were used for immunocytochemical study.
occurring as the sarcopenia and/or dynapenia (Clark andManini,
2008; Aagaard et al., 2010). In addition, which muscles would
be preferred for harvesting stem cells for future regeneration
therapies are important and interesting. However, present
results indicated that there were no significant differences in
the proliferation/differentiation/engraftment abilities of resident
cells from the variety of muscles with age and gender, when
there were isolated and exposed the same condition in culture
or transplanted in the damaged muscles of immunodeficient
animals. Of course individual differences apparently existed
between samples, but there were no constant tendencies in
the age, gender and muscle type and regions as shown in
Figures 11A,B and Supplemental Figure 3. Therefore, present
results further encourage to a notion that in vivo cellular
environment, such as the cachexia (Thomas, 2007; Cruz-Jentoft
et al., 2010; Berardi et al., 2014) with reduced physical activities,
may be a major cause for sarcopenia and/or dynapenia in the
human skeletal muscle. However, once they were isolated and
exposed the same condition, individual differences were reduced.
Consequently, the Sk-Cs therapy may be effective to repair
muscle regardless of the age, sex or muscle region that is used as
a donor for muscle stem cells.
In conclusion, the novelty of the present study is a
clear separation of the myogenic and the other multipotent
(nerve/vascular) stem cells are possible in the human Sk-
Cs, whereas this is difficult in the mouse. In addition, we
strongly recommend the following conditions for therapeutic
use of human skeletal muscle-derived cells. (1) For expansion
culture, dexamethasone should not be used continuously in
the proliferation medium, but may be used within the first
week in the awaking medium. (2) Cell expansion culture
should be limited to 3 passages for 21 days in total. (3) Cell
expansion culture should not be perform on enzymatically
isolated bulk cells; cells should be divided into Sk-DN/29+ and
Sk-34 fractions before culture. These three points are important
for eliminating the risks of karyotype abnormalities, and will
ensure sufficient safety. In addition, the following conditions
are necessary to obtain better in vivo transplantation results.
(1) Muscle samples should not be minced before enzymatic
digestion, and a milder enzymatic cocktail should be used as a
minimal digestive requirement (inhibit contaminating proteases,
etc.). If the residual muscle was apparent in this step, repeated
(additional) isolation for 1 h is available after changing to a new
enzymatic cocktail, while the cell survival ratio is reduced. (2)
Cell expansion culture should be performed separately for Sk-DN
and Sk-34 cells, as the cell engraftment ratio and differentiation
capacities in vivo are significantly reduced in combined culture.
(3) In addition, significant reductions of in vivo engraftment
capacity were also observed beyond 2 passages, even after
separate expansion, and this trend is more apparent for the
myogenic potential of Sk-DN cells. It is therefore possible that
the present method revealed efficient, stable and safety expansion
of the human skeletal muscle-derived stem cells, and this also
contributed to an active engraftment in vivo after transplantation.
Acknowledgments
This work was supported by the grant 2013–2014 Tokai
University School of Medicine, Project Research, and in part by
a Grant-in-aid for Scientific Research (C-24590303) from the
Ministry of Education, Science and Culture of Japan.
Supplementary Material
The Supplementary Material for this article can be found
online at: http://journal.frontiersin.org/article/10.3389/fphys.
2015.00165/abstract
Supplemental Figure 1 | Behavior of Sk-DN/29− cells after 62 days culture
with 3 passages. Debris are still observed (A). Cells are typically showing flat and
less characteristics (B,C).
Supplemental Figure 2 | Determination of HNA+ cells in the
immunoelectron microscopy. The method-1 is a using of higher-brightness
view as shown in (A). Black dots densities in the HNA+ nuclei (black arrows) are
clearly higher than negative nuclei (red arrows). However, this view is not suitable
for general morphology. Method-2 is a using of high magnification photograph as
shown in (B). In this magnification, DAB products can be detected even in the rare
black dots densities (black arrows). Bars in A = 10µm, and in B = 2µm.
Supplemental Figure 3 | Side-by-side comparison of engraftment capacity
of the young (17 years-old), middle-aged (45 years-old), and old (79
years-old) subject derived Sk-34 and Sk-DN cells after 6 weeks of
transplantation. Age, gender, and muscle region depend particular trends are
not detectable in these photographs. (A,B) nude mouse TA muscle, (C,D) node
rat TA muscle.
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